COVID-19 Virus Infection

• EMA approval · 2026-08-12
  EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

  EC/EMA authorised Comirnaty (BioNTech) for COVID-19, an mRNA vaccine encoding SARS-CoV-2 spike protein.

• EMA approval · 2026-08-07
  EMA Authorised: Nuvaxovid (SARS CoV-2 (Original) recombinant spike protein;SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein) — Sanofi Winthrop Industrie

  EMA has authorised Nuvaxovid (SARS-CoV-2 original and Omicron XBB.1.5 recombinant spike proteins) for COVID-19 virus infection.

• EMA approval · 2026-07-16
  EMA Authorised: Bimervax (SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion dimer produced by recombinant DNA technology) — Hipra Human Health S.L.

  EMA authorised Bimervax, a SARS-CoV-2 RBD-fusion dimer vaccine, for COVID-19 infection.

• EMA approval · 2026-04-29
  EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

  Comirnaty (BioNTech) has been authorised by the EMA for use in COVID-19, with the active substance being mRNA encoding the SARS-CoV-2 spike …